BIOLASE announced it has been invited to participate in the 11th Annual Benchmark Discovery One-on-One Investor Conference taking place in New York City on December 1, 2022.
President and CEO, John Beaver, and CFO, Jennifer Bright, will host one-on-one meetings with investors and analysts during the event.
To schedule a one-on-one investor meeting with the company’s management, please contact BIOLASE’s investor relations firm, EVC Group, LLC, at tkehrli@evcgroup.com.
About BIOLASE
The company is a medical device business that develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 302 patented and 28 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients.
BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. The company has sold over 43,300 laser systems from 1998 through December 31, 2021 in over 80 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.
For updates and information on Waterlase iPlus, Waterlase Express, and laser dentistry, find the company online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.
BIOLASE, Waterlase, and Waterlase iPlus are registered trademarks of BIOLASE.
